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Abstract 
 
Currently in Portugal, universal screening of pregnant women for Cytomegalovirus 
(CMV) infection is not performed. However, it is recommended to screen all women 
attending preconception care. 
We aimed to assess women’s attendance to preconception care and if their serologic status 
regarding CMV was known and/or investigated in that consultation.  
In this cross-sectional study, we interviewed 240 women admitted to the obstetrical ward 
of a hospital in the Metropolitan Area of Porto (Portugal) about their adherence to 
preconception care and collected data regarding their CMV serologic status and its 
investigation.   
We found that 71,3% of the women who attended preconception care were not screened 
for CMV infection. Among primigravida, the screening rate was only of 30,4% (upper 
limit of CI95%: 44,8%). There were no statistically significant differences between the 
private and public sectors of healthcare. We observed attendance to preconception care is 
high (73,1%). For the population subgroup of the metropolitan area of Porto, attendance 
to preconception care is at least 66%, with a 95% confidence level. 
Portuguese guidelines stating a woman’s serologic status regarding CMV should be 
investigated in preconception care are not properly implemented. This suggests 
guidelines should assure the screening of previously non-screened women during 
pregnancy. 
 
 
Introduction 
 
Cytomegalovirus (CMV) causes the most prevalent congenital infection[1]. It belongs to 
the herpesviridae family and can be spread through body fluids such as saliva, urine, 
blood or genital secretions[2, 3]. The most important infectious source consists of toddlers 
attending day care[2]. Both primary and secondary infections can be vertically 
transmitted[4], although primary infections are thought to have a higher rate of 
transmission to the fetus[5]. When a CMV infection occurs in the mother, the placenta 
may become dysfunctional and fail to properly nourish and oxygenate the fetus[4], 
causing severe illness[5]. In fact, this infection is the first non-genetic cause of 
sensorineural hearing loss in newborns and the primary cause of congenital neurological 
handicap of infectious origin[2, 3].The earlier in pregnancy the infection occurs, the 
higher the rate of vertical transmission[6] and the more severe the complications to the 
fetus[2, 7]. 
CMV congenital infection affects 0,6-0,7% of all newborns[2, 8]. 40-65% of women of 
reproductive age are at risk for primary infection[9]and 0,6-1,4% are primarily infected 
with CMV during pregnancy[2]. Primary infection is usually asymptomatic, with fewer 
than 5% of pregnant women showing symptoms. Even when present, they are usually 
nonspecific[2]. This makes testing women upon clinical suspicion very inefficient. 
Pregnant women are also tested when consistent abnormalities are found in the 
ultrasound. However, Guerra et al concluded that when fetal infection status is 
unknown, ultrasound abnormalities predict symptomatic congenital infection in only 
35% of cases[10].  This infection is difficult to prevent since we are dealing with a 
ubiquitous virus[5]. The development of a vaccine is of high importance, since its needed 
investment is estimated in US $360 million, whereas providing care for children with 
congenital CMV infection amounts to $1.9 billion per year[3]. In spite of this, the 
availability of a CMV vaccine is at least 6-10 years away[11].  
Whether all pregnant women should or should not be screened is a highly-debated 
question[4]. Currently in Portugal the official recommendation is not to universally screen 
pregnant women for CMV infection, though it is recommended that women in 
preconception care be screened[12]. There are two main arguments supporting this 
decision[13]: one is the uncertainty of a bad prognosis for the infected fetuses, since 90% 
are asymptomatic at birth. Yet 15% of these develop symptoms later on[8]. The other is 
the lack of an approved treatment to be offered after a diagnosis is made[13, 14]. 
However, that paradigm is changing. Several studies have suggested the administration 
of CMV hyperimmune globulin during pregnancy may be associated with better 
outcomes in fetuses suspected of having congenital CMV infection[15, 16, 17]. Also, 
Leruez-Ville et al recently published their results showing valacyclovir (8g/day) given in 
pregnancy significantly increased the proportion of asymptomatic newborns from 43% 
without treatment to 82% with treatment. All 33 children who were asymptomatic at birth 
remained asymptomatic at 12 months of age[18, 19]. Valacyclovir has the best safety 
profile of the anti-CMV drugs and its administration in the first trimester was not 
associated with an increased risk of major birth defects[20]. This high dosage was 
extremely well tolerated both laboratorial and clinically, with an adherence to treatment 
over 90%[18]. Also, a recent study found that universal serologic screening (as opposed 
to screening only high-risk women or those with abnormal ultrasound findings) was the 
preferred and most cost-effective approach, as long as the treatment was effective in 47% 
of the cases[1]. In spite of the recommendations, many doctors in Portugal screen 
asymptomatic women during pregnancy[4]. 
Since universal screening during pregnancy is not recommended, the efficacy of 
preconception screening is of paramount significance. Knowing women’s serologic status 
prior to pregnancy allows for preventive care and facilitates an early-on diagnosis of a 
CMV infection during gestation.  
In this study, we investigated the success of preconception care in the metropolitan area 
of Porto, regarding women’s adherence and the investigation of their CMV serologic 
status prior to pregnancy. 
 
Methods 
 
Study Design and Participants 
In this cross-sectional study, we approached 240 pregnant and puerperal women admitted 
to the Obstetrics ward of a hospital in the metropolitan region of Porto (Portugal) and 
collected data regarding their age, education level, marital status, number of pregnancies 
and deliveries, and whether the current pregnancy was planned. If so, we asked if they 
attended preconception consultation and in which setting. We then investigated if their 
serologic status regarding CMV was previously known and/or investigated in that 
consultation. In marital status, unmarried couples are defined as two people living 
together for over two years. 
Data were collected from September 9th to November 28th 2016 by interviewing women 
in person and consulting their Pregnant Woman’s Health Booklet or electronic clinical 
records. We included all patients staying in the ward and able to respond at the time of 
visit, as long as informed written consent was provided. Ward visiting days were chosen 
by convenience, with caution to select different weekdays. Women under the age of 18 
were excluded. This study was approved by the institution's’ Ethics Committee. 
Data Measurement  
Maternal educational status (ES) was stratified in 4 strati, according to completion of:  
● no education, primary education, or lower secondary education (ES 1); 
● upper secondary education (ES 2);  
● post-secondary non-tertiary education (ES 3); 
● tertiary education (ES 4).  
Consultation settings were described as: PbGP - Public General Practitioner; PvO - 
Private Obstetrician and PbO – Public Obstetrician. PvO setting corresponds to women 
who attended only the private sector. For women who attended both, only the 
information regarding the public sector is considered. 
Statistics 
Data analysis was performed using IBM SPSS Statistics 23 software and statistical 
software package R, version 3.3.2. 
Maternal age was reported as median (interquartile range); all other variables were 
categorical and are reported as absolute or relative frequencies.  
Comparisons 
The participants were compared according to pregnancy planning. Planned pregnancies 
were compared according to attendance to preconception care and preconception 
consultation setting. 
For comparisons of distributions between groups, the Mann-Whitney and Kruskal Wallis 
tests were used for maternal age and for ordinal variables (gravidity, parity and 
educational status). When assumptions for the first weren’t verified, Pearson Chi-Square 
or Fisher's Exact Test were used for all other variables, reporting the 95% confidence 
interval for the proportions derived from Wilson method[21, 22]. p-values <0.05 were 
considered statistically significant.  
 
Results 
 
Baseline characteristics 
For the 240 pregnant and puerperal women included, median age was 32 years, with an 
interquartile range of 27 to 36 years. Of the 240 women, 171 had a planned pregnancy 
and of these, 125 attended preconception care. Of the 46 that did not attend, 35 (76,1%) 
were not interested in preconception consultation and 11 intended to attend. Information 
regarding CMV serologic status was accessible in electronic records for all women who 
chose the public setting. For the women who attended the private setting, Pregnant 
Woman’s Health Booklet was the only available source, but only 25 (59,5%) of the 
private setting consultations had record of the CMV serologic status. The complete data 
set was available for 45 primigravida (42,9% of the 105 primigravida included).  
Attendance to preconception care was 73,1% (CI95%: 66.0-79.2%) and 79.5% 
(CI95%:72.9-84.9%) including women who intended to attend but conceived before they 
had the opportunity to (Table 1). 
Pregnancy planning 
71,3% of all pregnancies were planned. A chi-square test was performed and a significant 
association was found between parity and marital status, and pregnancy planning: X2(2, 
N = 240) = 8,193 and 15,345, p=0,042 and 0,002, respectively. There was a higher 
proportion of women with a parity of 3 or more in the unplanned pregnancy group, as 
opposed to the planned pregnancy group; no association was found between gravidity or 
educational status and the planning of the pregnancy: X2(2, N = 240) = 2,112 and 6,691 
p=0,348 and 0,082, respectively.  
The categories with higher relative frequency for gravidity, parity, educational and 
marital status in not vs planned pregnancy were 1 vs 1, 1 vs 1, ES2 vs ES3 and single vs 
married, respectively. Since gravidity, parity and educational status are ordinal variables, 
we also performed a Mann-Whitney test to evaluate these variables’ distribution. The two 
groups differed significantly in educational status distribution (Mann–Whitney U = 4894, 
n1 = 68 n2 = 171, p<0.05 two-tailed), and maternal age (Mann–Whitney U = 4080, n1 = 
68 n2 = 171, p<0.001 two-tailed) with women who planned the pregnancy being older 
and having a greater mean rank than the ones with an unplanned pregnancy (126,38 vs 
105,93) (Table 2). 
Preconception care 
Fisher’s exact test, two-tailed, was performed and a significant association was found 
between educational and marital status, and attendance to preconception care, p<0,001 
and <0,05, respectively). Based on Mann-Whitney, these groups also differed 
significantly with respect to maternal age (Mann–Whitney U = 1750,5, n1 = 125 n2 = 
115, p< 0.001, two-tailed). (Table 2). 
Based on bivariate analyses, PbGP and PvO settings differed significantly with respect to 
maternal age (Mann–Whitney U = 1009,5, n1 = 73  n2 = 42, p = 0.002 two-tailed) and 
educational status (Fisher’s exact test, p=0.002 two-tailed), with PvO setting having older 
individuals, with a higher education status.   
There were no significant differences in the distribution of gravidity and parity between 
all preconception care settings. All differences between PbGP and PbO were 
nonsignificant. 
There’s a tendency for different distributions of education and marital status between PvO 
and PbO groups (p<0.1 applying Fisher’s Exact Test), with PbO having a tendency for 
lower ES and more unmarried couples. These differences might be nonsignificant because 
of the small sample size (higher sample power = 47,6%). (Table 2). 
CMV serologic status 
A total of 108 women had attended preconception care and had Pregnant Woman’s Health 
Booklet or electronic clinical records filled in. Of these, 20 had a previously known 
serologic CMV status. Of the 20 with previously known serologic CMV status, 4 (20%) 
hadn’t had previous contact with the virus, and only 2 were screened before the current 
pregnancy. Of the 16 who had previous contact with CMV, only 1 (6.3%; CI95%: 1.1-
28.3%) was screened prior to the current pregnancy. 
Screening rate for those with previously unknown serologic status was 31.8% 
(CI95%:23.0-42.1%). 
Screening rates did not differ significantly among pre-conception care settings. For all 
settings, 71.3% (CI95%: 62.5-79.0) of the women weren’t screened, and among 
primigravida screening rate did not reach 31% (CI95%: 19.1 – 44.8%); the highest 
screening rate for primigravida occurred in the PbGP setting (33,3%) (Table 3). 
 
Discussion 
 
We found that 71,3 % of all women with available data were not screened for CMV 
infection in preconception care. This is a very clinically relevant proportion considering 
the guideline in Portugal states that every woman who attends preconception care should 
be tested for CMV infection. We found no statistically significant differences in screening 
rates among pre-conception care settings.  This could suggest both general practitioners 
and obstetricians are similarly aware of CMV screening in preconception care. However, 
40% of women who attended the private sector didn’t have this information filled in in 
the Pregnant Women’s Health Booklet, so it is possible the screening was preformed but 
not registered. Moreover, 68,2% of women whose serologic status regarding CMV was 
unknown were not screened and 2 of the 4 women who were seronegative in the last test 
were not tested again before the current pregnancy. Looking at the primigravida group, 
for whom this preconception consultation was the first opportunity to be tested, we find 
that the general screening rate was only of 30,4% (upper limit of CI95%: 44,8%), with a 
higher screening rate in the PbGP setting, although there is no significant difference from 
other settings. This means the screening rate for primigravida is under 50%. 
We observed that attendance to preconception care is high (73,1%) and even higher 
including women who intended to attend but conceived before they had the opportunity 
to (79,5%). We can conclude that for the population subgroup of the metropolitan area of 
Porto, attendance to preconception care is at least 66%, with a confidence level of 95%. 
An unexpected finding was that the CMV serologic status in preconception consultations 
was only filled in in 57% of the investigated Pregnant Woman’s Health Booklets. These 
results refer to the private setting, since we only checked the booklets of the women who 
chose exclusively this sector.  
In our study, women who attend preconception care are older, more frequently married 
and have a higher education status. The same characteristics are associated with women 
who planned the pregnancy. Other studies have shown higher education levels are 
associated with lower CMV seroprevalence[9]. Planned pregnancies are also associated 
with parity, seeing that this group has a lower frequency of women with a parity ≥ 3 than 
the unplanned group. 
No significant differences were found between the PbGP and PbO groups for any of the 
characteristics assessed, likely due to the small sample size in the PbO group. 
Our research is not without limitations. Sampling was performed with a nonprobability 
method of convenience. However, we attempted to minimize selection bias by choosing 
different weekdays for ward visiting. For some of the sub analyses, sample size was small. 
However, for our main outcome (prediction of screening rate for women who attended 
preconception care) sample power was over 90%, with a significance level of 0,05. Some 
of the women included in the “single” marital status may relate to women living together 
with their partners for under 2 years. 
Given the current situation, where universally screening pregnant women for CMV 
infection is not recommended, testing women in preconception care is fundamental, so 
doctors pay more attention to suggestive symptoms and a primary infection may be 
detected early on[13]. Our findings reveal the current strategy is not efficiently 
implemented. This raises the question of whether women who are not screened in 
preconception care should be screened in the first consultation during pregnancy.  
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Table 1. Demographic and Clinical Characteristics of Participants 
 
 N TOTAL SAMPLE 
TOTAL 240 240 
MATERNAL AGE (years) 240 32 (27 – 36) 
GRAVIDITY 240  
• 1  105 (43,8) 
• 2  80 (33,39) 
• 3+  55 (22,9) 
PARITY 240  
• 0  12 (5) 
• 1  126 (52,5) 
• 2  84 (35) 
• 3+  18 (7,5) 
PLANNED PREGNANCY 240 171 (71,3) 
PRECONCEPTION CARE 171  
• YES  125 (73,1) 
Public General Practioner (PbGP)  73 (58,4) 
Public Obstetrician (PbO)  10 (8) 
Private Obstetrician (PvO)  42 (33,6) 
 CMV STATUS FILLED IN 42 25 (59,5) 
• NO  46 (26,9) 
 Motive   
Not interested  35 (76,1) 
Intended to  11 (23,9) 
EDUCATION STATUS* 240  
ES 1  69 (28,7) 
ES 2  70 (29,2) 
ES 3  82 (34,2) 
ES 4  19 (7,9) 
MARITAL STATUS 240  
Single  93 (38,8) 
Married  98 (40,8) 
Unmarried couple  39 (16,3) 
Divorced  10 (4,2) 
Maternal age is presented as median (interquartile range), the other variables as numbers (%). 
*ES 1- no education, primary education, or lower secondary education; ES 2 - upper secondary 
education; ES 3 - post-secondary non-tertiary education; ES 4 - tertiary education. 
 Table 2. Association Between Demographic/Clinical Characteristics and Pregnancy Planning, Healthcare Setting and Attendance to Preconception Care 
 
 PREGNANCY PLANNING HEALTHCARE SETTING ATTENDANCE TO PRECONCEPTION 
CARE 
 UNPLANNED 
PREGNANCY 
PLANNED 
PREGNANCY 
X2 P 
VALUE 
MANN-
WHITNEY 
p VALUE 
PbGP PvO PbO p VALUE YES NO p VALUE 
TOTAL (n=240) 69 (28,7) 171 (71,3)   73 (58.4) 42 (33.6) 10 (8.0)  125 (73.1) 46 (26.9)  
MATERNAL 
AGE (years) 
29 (23-34) 33 (29-36)  **<0,001 *33 
(29.5-35.5)* 
34 
(32-38) 
32 
(29.5-35.5) 
*0.002 
33 (31-36) 29 (24-34) **<0,001 
GRAVIDITY   0,348 0,270     1 (42.4) 1/2 (37.0) 0,791 
• 1 35 (50,7) 70 (40,9)   33 (45.2) 17 (40.5) 3 (30.0)     
• 2 19 (27,5) 61 (35,7)   27 (37.0) 13 (31.0) 4 (40.0)     
• 3+ 15 (21,7) 40 (23,4)   13 (17.8) 12 (28.6) 3 (30.0)     
PARITY   a0,042 0,342     1 (52,2) 1 (52,2) 0,1827 
• 0 2 (2,9) 10 (5,8)   5 (6.8) 2 (4.8) 3 (30.0)     
• 1 37 (53,6) 89 (52,0)   40 (54.8) 21 (50.0) 4 (40.0)     
• 2 23 (29,0) 64 (37,4)   25 (34.2) 17 (40.5) 3 (30.0)     
• 3+ 10 (14,5) 8 (4,7)   3 (4.1) 2 (4.8) 0     
EDUCATION 
STATUS c 
  
0,082 *0,030 #  b 
#0.002 
a0.083 ES3 (42,4) ES1 (54,3) 
**/## 
<0,001 
ES 1 23 (33,3) 46 (26,9)   18 (24.7) 1 (2.4) 2 (20.0)     
ES 2 25 (36,2) 45 (26,3)   23 (31.5) 10 (23.8) 4 (40.0)     
ES 3 19 (27,5) 63 (36,8)   24 (32.9) 25 (59.5) 4 (40.0)     
ES 4 2 (2,9) 17 (9,9)   8 (11.0) 6 (14.3) 0     
MARITAL 
STATUS   a0,002  b   a0.052 
Married 
(53,6) 
Single 
(47,8) #0,021 
Single 39 (56,6) 54 (31,6)   23 (31.5) 8 (19.0) 1 (10.0)     
Married 17 (24,6) 81 (47,4)   34 (46.6) 29 (69.0) 4 (40.0)     
Unmarried 
couple 
9 (5,8) 30 (3,5)   13 (17.8) 4 (9.5) 4 (40.0)     
Divorced 4 (13,0) 6 (17,5)   3 (4.1) 1 (2.4) 1 (10.0)     
Maternal age is presented as “median (interquartile range)”, the other variables as “number (%)”. For attendance to preconception care, the category with higher 
relative frequency is presented (%). 
ap<0.05, applying chi-square test X2; *p<0.05 and **p<0.001, applying Mann-Whitney test; bp<0.1, #<0.05 and ## p<0.001 applying Fisher’s exact test. In “Healthcare 
setting” comparison, values are significantly different compared to PvO group. All differences between PbGP and PbO were nonsignificant.  Attending and non-
attending groups did not differ significantly in gravidity and parity.  
c ES 1- no education, primary education, or lower secondary education; ES 2 - upper secondary education; ES 3 - post-secondary non-tertiary education; ES 4 - tertiary 
education. 
 
 
Table 3. Screening Rates. 
 
 Total Screened CI95 - Lower Limit CI95 - Upper Limit 
Available data 108 31 (28.7%) 21.0 37.9 
• PbGP 73 21 (28.8) 19.7 40.0 
• PvO 25 8 (32.0) 17.2 51.6 
• PbO 10 2 (20) 5.7 51.0 
Primigravida 46 14 (30.4) 19.1 44.8 
• PbGP 33 11 (33.3) 19.8 50.4 
• PvO 10 3 (30.0) 10.8 60.3 
• PbO 3 3 (100) 43.9 100 
Previously known  20 3 (15.0) 5.2 36.0 
• No Previous 
Contact 4 2 (50.0) 15.0 85.0 
• Previous 
Contact 16 1 (6.3) 1.1 28.3 
Previously unknown 88 28 (31.8) 23.0 42.1 
 
Screening rates are presented as “number (%)”. CI95 – 95% confidence interval for the 
screened proportion derived from Wilson method. All differences among preconception care 
settings were nonsignificant. 
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